CN111303156A - 一种依布替尼新晶型及其制备方法 - Google Patents
一种依布替尼新晶型及其制备方法 Download PDFInfo
- Publication number
- CN111303156A CN111303156A CN202010219072.0A CN202010219072A CN111303156A CN 111303156 A CN111303156 A CN 111303156A CN 202010219072 A CN202010219072 A CN 202010219072A CN 111303156 A CN111303156 A CN 111303156A
- Authority
- CN
- China
- Prior art keywords
- ibrutinib
- crystal
- crystalline form
- crystal form
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(min) | 流动相A(%) | 流动相B(%) |
0 | 65 | 35 |
15 | 65 | 35 |
30 | 45 | 55 |
35 | 45 | 55 |
48 | 20 | 80 |
55 | 20 | 80 |
55.01 | 65 | 35 |
65 | 65 | 35 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010219072.0A CN111303156A (zh) | 2020-03-25 | 2020-03-25 | 一种依布替尼新晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010219072.0A CN111303156A (zh) | 2020-03-25 | 2020-03-25 | 一种依布替尼新晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111303156A true CN111303156A (zh) | 2020-06-19 |
Family
ID=71145949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010219072.0A Pending CN111303156A (zh) | 2020-03-25 | 2020-03-25 | 一种依布替尼新晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111303156A (zh) |
-
2020
- 2020-03-25 CN CN202010219072.0A patent/CN111303156A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108864077B (zh) | 小檗碱有机酸盐的固体形式及其制备方法 | |
EP2411394B1 (en) | Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one | |
JP6691218B2 (ja) | 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法 | |
WO2006024863A1 (en) | Stable crystal form of imatinib mesylate and process for the preparation thereof | |
JP6657269B2 (ja) | Pci―32765の結晶型aの調製方法 | |
WO2019019959A1 (zh) | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 | |
CN111777595A (zh) | 一种环己烷甲酰胺类化合物的新晶型及其制备方法 | |
CN113840604A (zh) | Jak2抑制剂的结晶形式 | |
EP3201190A1 (en) | Crystalline form of afatinib dimaleate | |
TW202033517A (zh) | Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物 | |
EP3805229A1 (en) | Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof | |
CN114437084A (zh) | 杂环类化合物及其制备方法和应用 | |
CN105503854A (zh) | 一种达沙替尼无水合物的新晶型物及其制备方法 | |
CN108976234B (zh) | 一种依鲁替尼和糖精的共无定型物及其制备方法 | |
CN109232582B (zh) | 拉洛替尼硫酸氢盐晶型及其制备和应用 | |
CN111303156A (zh) | 一种依布替尼新晶型及其制备方法 | |
EP4303212A1 (en) | Hydroxytyrosol nicotinamide eutectic crystal, and preparation method therefor and composition thereof | |
CN104961680A (zh) | N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的盐酸盐及其多晶型 | |
CN114008023B (zh) | 索吡溴铵的晶型及其制备方法 | |
CN111620879B (zh) | Pf-06651600马来酸盐,晶型及其制备方法 | |
CN112125910A (zh) | 一种阿伐普替尼晶型及其制备方法 | |
WO2019211870A1 (en) | Polymorphic forms of ibrutinib | |
CN110964017A (zh) | 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途 | |
CN109796400B (zh) | 一种甲苯磺酸索拉菲尼晶型及其制备方法 | |
EP4114835A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 226200 No.3 Jiangfeng Road, Qidong life and Health Industrial Park, Nantong City, Jiangsu Province Applicant after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Applicant after: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd. Applicant after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203 Shanghai Pudong New Area China (Shanghai) Free Trade Pilot Area Zhangheng Road 1999 Building 3 Applicant before: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd. Applicant before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Applicant before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address after: 201203 Shanghai Pudong New Area China (Shanghai) Free Trade Pilot Area Zhangheng Road 1999 Building 3 Applicant after: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd. Applicant after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Applicant after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203 Shanghai Pudong New Area China (Shanghai) Free Trade Pilot Area Zhangheng Road 1999 Building 3 Applicant before: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd. Applicant before: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd. Applicant before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
CB02 | Change of applicant information | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200619 |
|
WD01 | Invention patent application deemed withdrawn after publication |